Skip to main content

Advertisement

SpringerLink
Log in

Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the efficiency and toxicities of nedaplatin and paclitaxel in patients with metastatic carcinoma of the esophagus.

Methods

Thirty-nine untreated patients with confirmed metastatic tumors were enrolled. Patients were treated with nedaplatin 80 mg/m2 and paclitaxel 175 mg/m2 on day 1. Treatment was repeated every 21 days.

Results

Thirty-six patients were eligible to be evaluated to have had a response. The overall response rate was 43.6% (17/39), with complete response and partial response rates of 2.6 and 41%, respectively. The median progression-free survival and overall survival time was 6.1 and 10.3 months, respectively. Grade 3/4 toxicities were only observed in six patients [neutropenia in three patients (7.7%) and nausea/vomiting in three patients (7.7%)].

Conclusion

Comparing to other regimens, combination of nedaplatin and paclitaxel achieved an encouraging clinical outcome, with relatively minimal toxicities for patients with metastatic esophageal carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086–1091

    Article  PubMed  CAS  Google Scholar 

  2. Alberts DS, Fanta PT, Running KL, Adair LP Jr, Garcia DJ, Liu-Stevens R, Salmon SE (1997) In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol 39:493–497

    Article  PubMed  CAS  Google Scholar 

  3. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33:1216–1220

    Article  PubMed  CAS  Google Scholar 

  4. Cho SH, Chung IJ, Song SY, Yang DH, Byun JR, Kim YK, Lee JJ, Na KJ, Kim HJ (2005) Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer. J Korean Med Sci 20:618–623

    PubMed  CAS  Google Scholar 

  5. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46

    Article  PubMed  CAS  Google Scholar 

  6. El-Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris A, Philip PA (2004) A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol 15:960–965

    Article  PubMed  CAS  Google Scholar 

  7. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M (1992) Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22:172–176

    PubMed  CAS  Google Scholar 

  8. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP (1998) Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826–1834

    PubMed  CAS  Google Scholar 

  9. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O’Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP (1999) Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270–3275

    PubMed  CAS  Google Scholar 

  10. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP (2007) Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 18:898–902

    Article  PubMed  CAS  Google Scholar 

  11. Jemal A, Siegel R, Ward E (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130

    Article  PubMed  Google Scholar 

  12. Kanai M, Matsumoto S, Nishimura T (2007) Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. Int J Clin Oncol 12:224–227

    Article  PubMed  CAS  Google Scholar 

  13. Kawai Y, Taniuchi S, Okahara S (2005) Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 28:1385–1388

    Article  PubMed  CAS  Google Scholar 

  14. Kurata T, Tamura K, Yamamoto N, Nogami T, Satoh T, Kaneda H, Nakagawa K, Fukuoka M (2004) Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. Br J Cancer 90:2092–2096

    PubMed  CAS  Google Scholar 

  15. Kurita H, Yamamoto E, Nozaki S, Wada S, Furuta I, Kurashina K (2004) Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 40:1000–1006

    Article  PubMed  CAS  Google Scholar 

  16. Levard H, Pouliquen X, Hay JM, Fingerhut A, Langlois-Zantain O, Huguier M, Lozach P, Testart J (1998) 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French associations for surgical research. Eur J Surg 164:849–857

    Article  PubMed  CAS  Google Scholar 

  17. Millar J, Scullin P, Morrison A, McClory B, Wall L, Cameron D, Philips H, Price A, Dunlop D, Eatock M (2005) Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer 93:1112–1116

    Article  PubMed  CAS  Google Scholar 

  18. Okuda K, Hirose T, Ishida H, Kusumoto S, Sugiyama T, Ando K, Shirai T, Ohnishi T, Horichi N, Ohmori T, Adachi M (2008) Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 61:829–835

    Article  PubMed  CAS  Google Scholar 

  19. Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A (2002) Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 86:669–673

    Article  PubMed  CAS  Google Scholar 

  20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  21. Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, Abbruzzese JL, Southwest Oncology Group Study (2004) Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a southwest oncology study group. Invest New Grugs 22:91–97

    Article  CAS  Google Scholar 

  22. Vestermark LW, Sørensen P, Pfeiffer P (2008) Chemotherapy to patients with metastatic carcinoma of the esophagus and gastro-esophageal junction. A survey of a Cochrane review. Ugeskr Laeger 170:633–636

    PubMed  Google Scholar 

  23. Zhang X, Shen L, Li J, Li Y, Li J, Jin M (2008) A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol 31:29–33

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Oncology, Tumor Center, West China Hospital, Sichuan University, 610041, Chengdu, People’s Republic of China

    Youling Gong, Li Ren, Lin Zhou, Jiang Zhu, Meijuan Huang, Xiaojuan Zhou, Jin Wang, You Lu & Mei Hou

  2. State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 610041, Chengdu, People’s Republic of China

    Youling Gong, You Lu & Yuquan Wei

Authors
  1. Youling Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Li Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiang Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meijuan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaojuan Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. You Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mei Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yuquan Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Ren.

Additional information

Y. Gong and L. Ren contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gong, Y., Ren, L., Zhou, L. et al. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer Chemother Pharmacol 64, 327–333 (2009). https://doi.org/10.1007/s00280-008-0874-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0874-8

Keywords

Search

Navigation